Malignant melanoma therapy by chemotherapy and autoimmunity induced by cytokine

Cancer Biother Radiopharm. 2009 Apr;24(2):237-41. doi: 10.1089/cbr.2008.0552.

Abstract

Purpose: The aim of this study was to evaluate the effect of combining dacarbazine (DTIC) and granulocyte/macrophage colony-stimulating factor (GM-CSF) with interleukin-2 (IL-2) in patients with advanced malignant melanoma.

Methods: Twenty-seven (27) patients with advanced malignant melanoma received dacarbazine (500 mg/m(2)/days 1-2, intravenously), GM-CSF (175 ug/m(2)/days 3-6, subcutaneously), and interleukin-2 (400 MIU/m(2)/days 7-10, subcutaneously). Each treatment cycle required 21 days to completion.

Results: Time to progression was 7-11 months. The total effective rate was 44.4%, and the combination of chemotherapy, GM-CSF, and IL-2 had low toxicity.

Conclusions: The combination of DTIC with GM-CSF and IL-2 is feasible and possibly efficacious for clinical use.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Autoimmunity / drug effects
  • Combined Modality Therapy
  • Dacarbazine / administration & dosage
  • Dacarbazine / adverse effects
  • Drug Interactions
  • Female
  • Granulocyte-Macrophage Colony-Stimulating Factor / administration & dosage
  • Granulocyte-Macrophage Colony-Stimulating Factor / adverse effects
  • Humans
  • Immunotherapy
  • Interleukin-2 / administration & dosage
  • Interleukin-2 / adverse effects
  • Male
  • Melanoma / drug therapy*
  • Melanoma / immunology
  • Middle Aged
  • T-Lymphocytes / immunology

Substances

  • Interleukin-2
  • Dacarbazine
  • Granulocyte-Macrophage Colony-Stimulating Factor